Risk Factors for Adverse Symptoms During Dipeptidyl Peptidase-IV Inhibitor Therapy: A Questionnaire-Based Study Carried Out by the Japan Pharmaceutical Association Drug Event Monitoring Project in Kumamoto Prefecture

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Drug Safety

• Publication date

  2013-06-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40264-013-0077-zPMID 23743694
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?

  2012cited by this paper
• Managing Diabetes in Patients with Chronic Liver Disease

  2012cited by this paper
• Minireview: The role of the autonomic nervous system in mediating the glucagon response to hypoglycemia.

  2012cited by this paper
• Predictors of Emergency Department and Outpatient Visits for Hypoglycemia in Type 2 Diabetes: An Analysis of a Large US Administrative Claims Database

  2012influential reference
• Comparing Adverse Event Rates of Oral Blood Glucose-Lowering Drugs Reported by Patients and Healthcare Providers

  2011cited by this paper
• Regulation of glucagon secretion by incretins

  2011cited by this paper
• Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes.

  2011cited by this paper
• Tolerability of dipeptidyl peptidase-4 inhibitors: a review.

  2011cited by this paper
• Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin.

  2011influential reference
• Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.

  2010cited by this paper
• The missing voice of patients in drug-safety reporting.

  2010cited by this paper
• Alcohol and type 2 diabetes. A review.

  2010cited by this paper
• Sex differences in glucose levels: a consequence of physiology or methodological convenience? The Inter99 study

  2010cited by this paper
• Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes

  2010cited by this paper
• A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes

  2010cited by this paper
• Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.

  2009cited by this paper
• Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline.

  2009cited by this paper
• Gender‐specific care of diabetes mellitus: particular considerations in the management of diabetic women

  2008cited by this paper
• Nationwide Survey of Subjectively Reported Adverse Drug Reactions in Sweden

  2008cited by this paper
• Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women.

  2008cited by this paper
• High‐fat diet‐induced hepatic steatosis reduces glucagon receptor content in rat hepatocytes: potential interaction with acute exercise

  2007influential reference
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

  2007cited by this paper
• Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes*

  2007cited by this paper
• Sex Differences in Hepatic Gluconeogenic Capacity After Chronic Alcohol Consumption

  2007cited by this paper
• Efficacy and tolerability of the dipeptidyl peptidase‐4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes

  2006cited by this paper
• Glucose kinetics differ between women and men, during and after exercise.

  2006cited by this paper
• Hypoglycemia associated with liver disease and ethanol.

  1989cited by this paper

• Techniques for the determination of dipeptidyl peptidase IV and screening of its inhibitors

  2025cites this paper
• Prevalence and Predictors of Adverse Events Associated With Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetic Patients: A Cross-sectional Study

  2024cites this paper
• Studi Pustaka Efek Samping Obat Antidiabetik Oral pada Pasien Geriatri dengan Diabetes Melitus Tipe 2

  2024cites this paper
• Management of type 2 diabetes in patients with compensated liver cirrhosis: Short of evidence, plenty of potential.

  2023cites this paper
• Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review.

  2023cites this paper
• Targeted Pharmacovigilance for Dipeptidylpeptidase-4 (DPP-4) Inhibitors: A Cross-Sectional Study

  2022cites this paper
• Antidiabetic agents in patients with hepatic impairment

  2019cites this paper
• Adverse drug reactions monitoring of newer oral hypoglycemic drugs in a tertiary care hospital of North India: a prospective study

  2017influential citation
• Safety analysis of zolpidem in elderly subjects 80 years of age or older: adverse event monitoring in Japanese subjects

  2016cites this paper
• Prescription of triazolam for the elderly in Japan: A sub-analysis of the drug event monitoring project by the Japan Pharmaceutical Association

  2016cites this paper
• Adverse drug reaction monitoring of newer oral anti-diabetic drugs - A pharmacovigilance perspective

  2016influential citation
• Antidiabetic therapy in post kidney transplantation diabetes mellitus.

  2015cites this paper
• Higher Risk of Sulfonylurea-associated Hypoglycemic Symptoms in Women with Type 2 Diabetes Mellitus

  2015influential citation
• Sex differences in type 2 diabetes: focus on disease course and outcomes

  2014cites this paper
• Absence of gargling affects topical adverse symptoms caused by inhaled corticosteroids in females

  2014cites this paper
• Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus

  2014cites this paper
• Younger Females Are at Greater Risk of Vasodilation-Related Adverse Symptoms Caused by Dihydropyridine Calcium Channel Blockers: Results of a Study of 11,918 Japanese Patients

  2014cites this paper